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ABSTRACT
Background: Differential diagnosis between malignant pleural mesothelioma 
(MPM) and benign mesothelial conditions is still challenging and there is a lack of 
useful markers. Programmed cell death 4 (PDCD4) is a well-known tumor suppressor 
gene in several cancers, its post-transcriptional activity is directly controlled by miR-
21, whose over-expression has been recently reported in MPM compared to normal 
mesothelium. Aim of this study was to test this suppressor gene as a possible new 
marker of malignant transformation in mesothelial cells, as well as a new prognostic 
marker.
Methods: PDCD4 nuclear expression was assessed by immunohistochemistry 
(IHC) in 40 non-neoplastic pleural (NNP) and 40 MPM formalin-fixed and paraffin-
embedded specimens. PDCD4 and miR-21 expressions were analyzed by qRT-PCR in 
all cases. In situ hybridization (ISH) of miR-21 was performed in 5 representative 
cases of both groups. The prognostic relevance of PDCD4 was assessed in a public 
available gene expression dataset.
Results: IHC showed that PDCD4 nuclear expression was significantly lower in 
MPM than in NNP. PDCD4 was down-regulated, whereas miR-21 was over-expressed 
in MPM cases compared to NNP ones. ISH detected miR-21 only in MPM specimens. 
Down-expression of PDCD4 was found significantly associated with short overall 
survival in publicly available data.
Conclusions: These findings highlighted a switch between PDCD4 and miR-21 
expression in MPM. Further studies should assess the diagnostic reliability of these 
two markers for MPM in biopsy and effusion specimens.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is the most 
lethal tumor arising from the mesothelial cells that line the 
serosal cavities and it is strongly associated to the long-
term inhalation of asbestos fibers. Although infrequent, 
MPM global incidence is rising dramatically and it is 
expected to peak in the next decade, in relation with the 
long latency time (approximately 40 years) [1].
According to the World Health Organization (WHO), 
there are three main MPM histotypes. The epithelioid 
type is the most common and it is mainly characterized 
by epithelial-shaped cells expressing epithelial markers 
such as cytokeratin 5/6; the sarcomatoid type is composed 
by spindle cells which express mesenchymal markers as 
vimentin and S100A4; the biphasic type is composed by 
both epithelial-shaped and spindle cells [2]. Typically, 
MPM is unresponsive to conventional therapies and the 
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mean overall survival ranges only between 9 and 12 
months [3]. Molecular pathways implicated in MPM are 
still largely unknown, but it is clear that more than a single 
alteration triggers tumorigenesis and progression. Asbestos 
fibers may trigger the transformation of mesothelial 
cells through the generation of reactive oxygen species, 
inducing a genomic damage and causing the release of 
different pro-inflammatory and carcinogenetic cytokines 
by the mesothelial and inflammatory cells (e.g. tumor 
necrosis factor-α, several interleukins, transforming 
growth factor-β, and platelet-derived growth factor) 
[4]. All these mechanisms are linked to the inactivation 
of oncosuppressor genes, such as the complex cyclin-
dependent kinase inhibitor 2A (CDKN2A)/alternative 
reading frame (ARF), retinoblastoma, and p53 [5]. 
Moreover, mutations of NF2 gene have been reported 
in MPM; NF2 encodes for the protein merlin, which is 
a negative regulator of the mTOR-related pathway [4, 
5]. Recently, germline mutations of BRCA1-associated 
protein (BAP1, another oncosuppressor gene encoding 
for a nuclear ubiquitin C-terminal hydrolase regulating 
the gene expression) have been linked to a form of 
familiar MPM and loss of BAP1 has been proposed as 
a promising marker of malignancy in mesothelial cells 
[6, 7]. Epigenetic alterations have also been described in 
MPM, including promoter methylation of oncosuppressor 
genes such as E-cadherin, fragile histidine triad, retinoic 
acid receptor-β, and WNT inhibitor factor 1 [8]. miRNA 
dysregulation has also been found in MPM [9], possibly 
involved in carcinogenesis [10]. In particular, several 
papers reported miR-21 over-expression in MPM 
[11–13] and we recently demonstrated its reliability as 
MPM marker [14]. However, miRNA quantification 
is not easily available in all laboratories and it would 
be preferable to use the more common immuno-cyto-
chemistry. MiR-21 has been shown to specifically 
regulate Programmed Cell Death 4 (PDCD4) expression 
at post-transcriptional level [15], but no studies have 
addressed PDCD4 expression in MPM yet. PDCD4 is 
an oncosuppressor gene whose expression is frequently 
altered in cancer, causing the disruption of the apoptotic 
machinery. PDCD4 plays its function at both mRNA 
transcriptional and translational level. Specifically, 
PDCD4 inhibits the translation of several oncoproteins 
by suppressing the activity of eukaryotic initiation factors 
4A and 4G (eIF4A, eIF4G) and affects gene transcription 
by interacting with the JNK/c-Jun/AP-1 pathway. The 
genes mainly regulated by the PDCD4 activity are p21, 
Cdk4, ornithine decarboxylase and carbonic anhydrase 
II16. The nuclear PDCD4 expression decrease during 
carcinogenesis can be considered as a possible indicator 
of malignant transformation [16, 17] and a suitable 
immunohistochemical marker to distinguish MPM from 
benign mesothelial conditions [13, 14].
Aim of this study is the evaluation of PDCD4 and 
miR-21 expressions both at RNA and protein levels in 
two cohorts of MPM and non-neoplastic pleural (NNP) 
samples. Moreover, the prognostic relevance of PDCD4 
was assessed in a publicly available MPM gene expression 
dataset, testing for associations between PDCD4 and 
overall survival.
RESULTS
In MPM specimens, nuclear PDCD4 positive 
immunostaining was scored 0 in 22 cases, 1 in 12 cases, 
and 2 in 5 cases, 3 in one case; significantly lower with 
respect to NNP specimens (p=8.64e-05), where nuclear 
PDCD4 positive immunostaining was scored 0 in 3 cases, 
1 in 25 cases, 2 in 9 cases and 3 in 3 cases (Figure 1A). 
Focusing on MPM histological subtypes, Mann–Whitney 
Wilcoxon test highlighted significantly higher scores 
for epithelioid subtype with respect to the joint group 
of biphasic and sarcomatoid samples (p=0.037; Figure 
1B). There are no statistically significant differences 
between samples of normal pleura and samples of pleuritis 
(p=0.54), whereas the comparison between cases of 
pleuritis and mesotheliomas provides a significant p-value 
(p=0.05).
PDCD4 and miR-21 expressions were investigated 
in MPM and NNP specimens also by qRT-PCR analysis 
(Figure 1C-1F, results reported in terms of ΔCt values). 
PDCD4 expression was significantly lower in MPM than 
NNP specimens (p=0.0003, Figure 1C), with significantly 
higher expression in epithelioid MPMs with respect to 
biphasic and sarcomatoid cases (p=0.003, Figure 1D). 
Conversely, miR-21 was found over-expressed in MPM 
samples compared to NNP ones (p=1.03e-08, Figure 1E), 
with lower expression in epithelioid cases compared to 
the other histopathological subtypes (p=0.033, Figure 1F). 
In situ hybridization analysis detected miR-21 in MPM 
specimens, while all the NNP samples analyzed were 
negative (Figure 2).
Finally, PDCD4 survival analysis performed on 
the available public dataset [18] revealed a significant 
association between low expression levels of PDCD4 and 
short-term overall survival (p=0.024 Log-rank test, Figure 
3). The survival model was not altered by the inclusion 
of confounding factors as gender, age and exposure 
to asbestos, which showed coefficients that were not 
statistically significant (p>0.4).
DISCUSSION
MPM is one of the most lethal malignancies 
worldwide. Available therapies are mostly ineffective 
and both histological and cytological diagnoses remain 
a challenging task for pathologists [19]. Indeed, the 
strongest criterion to detect malignancy is the presence of 
stromal invasion within the context of aberrant mesothelial 
cells proliferation, whereas typically benign mesothelial 
proliferation associated with organizing pleuritis lacks 
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the invasion by the mesothelial component [2]. However, 
in some cases cytological and morphological features 
of benign conditions may resemble those of MPM since 
glands or other type of cells may result incorporated 
into the thickened pleura, mimicking invasion [2, 20]. 
Therefore, in many cases these features alone are not 
always sufficient to achieve a definitive diagnosis and 
supportive ancillary tests would be necessary. The 
Figure 1: Immunohistochemical and qRT-PCR data analysis in MPM and NNP cohorts. (A-B) distribution of IHC-based 
nuclear scores of PDCD4 in the two cohorts (A) and in the MPM histological subtypes (B); (C-D) PDCD4 expression in terms of ΔCt 
values in the two cohorts (C) and in the MPM histological subtypes (D); (E-F) miR-21 expression in terms of ΔCt values in the two cohorts 
(E) and in the MPM histological subtypes (F). Legend for the MPM subtypes: E: epithelioid, B: biphasic, S: sarcomatoid.
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International Mesothelioma Interest Group recommended 
the use of at least four immunohistochemical markers 
(two in favor of and two against MPM diagnosis), 
however, diagnostic approaches to differentiate malignant 
versus benign mesothelial lesions using known markers 
(e.g. desmin, p53, IMP3, GLUT-1, CD146, and CD147) 
have proven to be inadequate [2]. Most recently, BAP1 
immunostaining has been introduced demonstrating a 
diagnostic specificity of 100%, but sensitivity is still low 
since it does not exceed 60% [21]. Fluorescence in situ 
hybridization (FISH) for 9p21 has also been performed to 
this purpose, but the reported sensitivity and specificity 
for this technique are 61% and 100%, respectively 
[22]. Moreover, FISH is not yet available in all histo/
cytopathological laboratories, it is time consuming, 
expensive, and it requires skilled dedicated personnel. 
These limitations may determine unacceptable delay in 
diagnosis as well as false negatives with relevant socio-
economics and legal implications. miRNA quantification-
based tests as well as metabonomic analysis by proton 
nuclear magnetic resonance have been proposed as an 
effective alternative to solve this differential diagnosis [13, 
14, 23, 24]. However, despite the encouraging results, the 
limited accessibility to these approaches remarkably limits 
their application in the routine diagnostics. Therefore, the 
identification of new markers for MPM diagnosis remains 
a priority.
PDCD4 is a recently discovered onco-suppressor 
gene located at chromosome 10q24 that plays a crucial 
role in pro-apoptotic pathways and its impairment 
determines defective apoptosis. In the nucleus, PDCD4 
interacts with the translation initiation factors eIF4A and 
eIF4G and suppresses oncogenic pathways such as cell 
transformation, tumorigenesis and invasion, regulating 
several downstream effectors as p21, Cdk4, ornithine 
decarboxylase, carbonic anhydrase II, and JNK/c-Jun/
AP-1 [16]. PDCD4 loss or down-regulation has been 
correlated with tumor progression and poor prognosis in 
different tumors of thyroid, colon, esophagus, and ovary 
[25]. Moreover, studies on cell lines transfected with 
PDCD4 have shown its ability in inhibiting malignant 
behavior by the enhancement of apoptosis and chemo-
sensitivity, suggesting this gene as a potential regulatory 
marker for novel therapeutic strategies [26].
The main post-transcriptional regulator of PDCD4 
is represented by miR-21, an oncogenic microRNA that 
Figure 2: Representative figures of PDCD4 immunohistochemistry and in situ hybridization analysis of miR-21. (A-C) 
Normal mesothelial cells showed positive immunostain for nuclear PDCD4 (A) and undetectable level of miR-21 (C). (B-D) Malignant 
mesothelioma samples showed negative/low immunostain for PDCD4 (B) and high level of miR-21 (D).
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recognizes and directly binds the 3’-untraslated region 
of the PDCD4 transcript, blocking its translation into the 
protein [27]. MiR-21 over-expression has been reported in 
several cancers and, in some cases, this has been related 
to concurrent PDCD4 down-regulation [28–30]. miR-21 
over-expression in MPM has been described in several 
studies, but its correlation with PDCD4 expression has not 
been investigated yet. Our findings highlighted a reduction 
of nuclear PDCD4 immunostaining and a substantial 
switch between PDCD4 and miR-21 expression 
levels in MPM compared to NNP samples. This is in 
agreement with the available evidence for other tumors 
[28]. Moreover, PDCD4 expression in MPM showed 
a trend from epithelioid to biphasic and sarcomatoid 
subtypes, suggesting a role in tumor progression and, 
more specifically, in epithelial-mesenchymal transition 
(EMT). This has already been demonstrated in gastric, 
colorectal, lung, and breast cancer cell lines and it seems 
to be promoted and sustained by miR-21 over-expression 
[31–34]. In particular, loss of PDCD4 has been associated 
with increased Snail/Slug expression, two markers of the 
EMT process [31]. EMT in MPM was linked to a worse 
prognosis and our analysis performed on a publicly 
available microarray gene expression dataset showed 
the impact of PDCD4 down-regulation in shortening the 
overall survival [35].
There are some major limits of this study. Firstly, 
the relative small size of the series of samples in NNP and 
MPM cohorts limits the evaluation of PDCD4 as a marker 
of malignant transformation in mesothelial cells, although 
the observed incidence of MPM in our area is among the 
highest in the western countries. In particular, the two 
cohorts include few cases of pleuritis and sarcomatoid 
mesotheliomas. For our analyses, samples of normal 
pleura and pleuritis, as well as samples from biphasic and 
sarcomatoid mesotheliomas, were considered together 
since no statistically significant changes were observed in 
these pairs of sample groups in terms of both IHC scores 
and RT-PCR expression of PDCD4 (p>0.3). However, as 
highlighted above, in the MPM cohort Figures 1B, 1D and 
1F showed a trend across the three subtypes and we cannot 
exclude that, by increasing the number of both biphasic 
and sarcomatoid MPM cases, significant differences in 
PDCD4 expression may occur. Secondly, our study does 
not provide functional tests on mesothelial and MPM 
cell lines to directly demonstrate the effect of miR-21 
expression on PDCD4 and on cell behavior, which has to 
be necessarily performed in further studies considering 
also the downstream effectors of PDCD4. Nevertheless, 
these analyses have already been accomplished in other 
tumors, thus the link between the inverse expression of 
miR-21 and PDCD4 can be reasonably assumed also 
Figure 3: Kaplan-Meier curves of overall survival between PDCD4 expression-based subgroups. Survival analysis 
performed on published MPM microarray data divided according to high (gray curve) and low (black curve) PDCD4 expression values.
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in MPM [30]. Finally, the public dataset considered for 
the survival analysis includes only epithelioid MPM 
cases, therefore we were not able to assess differences 
of the overall survival on the other histotypes, which are 
expected to be even more significant between different 
levels of PDCD4 expression. An extensive search of 
possible datasets on MPM in the major databases for 
gene expression data such as GEO (Gene Expression 
Omnibus) and ArrayExpress showed that there are no 
datasets reporting all the three subtypes with available 
survival information on the patients. This aspect highlights 
the need of molecular data on large MPM cohorts across 
different subtypes to better assess novel diagnostic and 
prognostic markers.
MATERIALS AND METHODS
Histologic samples
From the archives of the Surgical Pathology 
and Cytopathology Unit of the University of Padova, 
formalin-fixed and paraffin-embedded (FFPE) biopsies of 
40 NNP (8 pleuritis and 32 normal pleura) and 40 MPM 
(26 epithelioid, 4 sarcomatoid, and 10 biphasic) were 
collected. All NNP and MPM cases derived from patients 
that underwent surgical resection of malignancy or pleura 
biopsy from 2010 to 2014. Moreover, these cases were not 
included in our previous studies. Clinical and pathological 
data are reported in Table 1. All cases were reviewed and 
the diagnoses were confirmed by 3 pathologists (AF, RC, 
LN) according to the WHO classification. This study was 
approved by the Institutional Ethical Review Board of 
Padova University and we followed the Institute’s ethical 
regulations of research on human tissues.
Immunohistochemistry
Immunohistochemistry was performed on 4-μm 
to 5-μm thick FFPE sections from each tissue sample. 
Staining was automatically performed using a fully 
automated system (Bond™-maX; Leica, Newcastle 
Upon Tyne, UK). Sections were pre-treated using heat-
mediated antigen retrieval with sodium citrate buffer 
(pH6, Epitope Retrieval Solution 1, Leica) for 30 
minutes at 99°C. Specimens were then incubated with 
rabbit polyclonal anti-PDCD4 (catalog No. HPA001032; 
Atlas Antibodies, Stockholm, Sweden; 1:200) and 
detected using the Bond Polymer Refine Detection Kit 
(Leica) according to the manufacturer’s protocols. The 
staining was visualized with 3,3’-diaminobenzidine 
(DAB) and the slides were lightly counterstained with 
hematoxylin. Sections were then dehydrated, cleared, 
and mounted. We used samples from FFPE human 
tonsil tissue as positive controls and serum without the 
primary antibody as negative control. PDCD4 nuclear 
expression was jointly scored by 2 pathologists (LN and 
RC) in a whole section for each case, unaware of any 
clinical information. A semi-quantitatively 4-tiered scale 
based on the percentage of positive cells was used, with 
0 indicating no stain, 1 indicating 1% to 30% staining, 2 
indicating 31% to 70% staining, and 3 indicating 71% to 
100% staining.
In situ hybridization
Reactions were performed on 4-μm to 5-μm 
thick FFPE sections from 5 NNP and 5 MPM cases 
randomly selected, using the GenPoint Catalyzed Signal 
Amplification System (DakoCytomation, Glostrup, 
Denmark) according to the manufacturer’s protocol. 
5’-biotin-labeled miR-21 miRCURY LNA microRNA 
detection probe (Exiqon, Vedbaek, Denmark) and the 
scrambled negative control probe (U6; Exiqon) at a final 
concentration of 200 nM were applied. The slides were 
finally counterstained with hematoxylin. Reactions were 
jointly assessed by 2 pathologists (LN and RC) and they 
were considered positive when granular cytoplasmic 
staining was present.
Table 1: Clinical and pathological data of MPM and NNP patients
N° mean age ± SD M/F
NNP
Pleuritis 8 53,45 ± 3,56 4/5
Normal Pleura 32 41,15 ± 5,93 23/8
Total 40 27/13
MPM
Epithelial 26 76,17 ± 4,23 18/8
Mixed 10 74,17 ± 4,51 7/3
Sarcomatoid 4 74,29 ± 6,11 3/1
Total 40 37/17
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RNA extraction
NNP and MPM samples were enriched in the 
neoplastic component by manual microdissection. Briefly, 
5 consecutive, unstained, 10-μm thick FFPE sections of 
each specimen were scraped in a 1.5 mL tube using the 
hematoxylin and eosin-stained slide as a guide. Total RNA 
was extracted using the RecoverAll Total Nucleic Acid 
Isolation Kit (Ambion, Austin, TX). All RNA extractions 
were assessed for the amount and purity of RNA with 
Qubit 3.0 (ThermoFischer Scientific, Waltham, MA) and 
stored at -80 °C until further use. To avoid any potential 
variation among assays, analyses were performed on all 
the extracts simultaneously.
Quantitative reverse transcriptase-polymerase 
chain reaction
PDCD4 reverse transcription was performed 
using 100 ng of total RNA, M-MLV Reverse 
Transcriptase (ThermoFischer Scientific, Waltham, 
MA), and 250 mM of random primers (ThermoFischer 
Scientific, Waltham, MA). PDCD4 primers (forward: 
5’-TGGAAAGCGTAAAGATAGTGTGTG-3’; reverse: 
5’-TTCTTTCAGCAGCATATCAATCTC-3’) were 
designed using the Probe-Finder software (roche-
appliedscience.com) and the respective probe was 
selected among the Universal Probe-Library (Roche 
Diagnostics, Mannheim, Germany). Experiments 
were then performed according to the standard 
protocol provided by the manufacturer, including 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
as housekeeping gene control (primers sequences: 
AGCCACATCGCTCAGACAC forward and 
GCCCAATACGACCAAATCC reverse) to normalize 
the unequal RNA amounts. Mature miR-21 (primer 
sequence: 5’-GATACCAAAATGTCAGACAGCC-3’) 
was retro-transcribed from 100 ng of total RNA with the 
SuperScript VILO cDNA Synthesis Kit (ThermoFischer 
Scientific, Waltham, MA) and quantified using the NCode 
miRNA quantitative reverse transcriptase-polymerase 
chain reaction (qRT-PCR) method (ThermoFischer 
Scientific, Waltham, MA), according to the manufacturer’s 
instructions [36]. miRNA Cycle Threshold (Ct) values 
were normalized to small nuclear RNA U6B (primer 
sequence: 5’-GTCAGACAGCC-3’). All the reactions 
were run in triplicate, including no-template controls, on 
the Light- Cycler 480 Real-Time PCR System (Roche 
Diagnostics).
Statistical analysis
Statistical significance was determined for IHC 
and qRT-PCR data by Mann–Whitney Wilcoxon test, 
comparing MPM and NNP cohorts and the MPM 
histopathological subtypes. Due to the low number of 
sarcomatoid MPM cases, biphasic and sarcomatoid 
MPM cases were considered jointly and compared to 
the epithelioid MPM cases. Differences between MPM 
and NNP cohorts in both miR-21 and PDCD4 qRT-
PCR data were evaluated in terms of delta-Ct (ΔCt = 
CtMPM – CtNNP) values. Prognostic relevance of PDCD4 
was assessed using a publicly available microarray gene 
expression dataset from de Reyniès et al. [18] (pre-
processed data from ArrayExpress with accession number: 
E-MTAB-1719); 20 MPM epithelioid samples were 
considered for overall survival analysis: 10 with low (i.e. 
<40th percentile) and 10 with high (i.e. >60th percentile) 
PDCD4 expression, considering the averaged signal across 
the corresponding probes. Patients were followed for a 
maximum of a 5-years overall survival. Log-rank test was 
performed comparing the Kaplan-Meier curves between 
the two sample groups defined above. All the analyses 
were performed using R statistical computing software 
(http://www.r-project.org), considering p values < 0.05 as 
statistically significant.
CONCLUSIONS
The proposed explorative study suggests 
that PDCD4 could be a reliable and helpful 
immunohistochemical marker for MPM. PDCD4 
diagnostic performances, as well as its prognostic 
relevance, should be tested in large MPM cohorts using 
both histological and cytological specimens. Functional 
experiments on PDCD4 and miR-21 pathway are needed 
to confirm our findings and to further investigate the 
molecular background underlying MPM oncogenesis.
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